Side-by-side · Research reference
P21vsVesugen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED8/36 cited
BAnimal-MechanisticHUMAN-REVIEWED5/43 cited
P21
CNTF-Derived Neuropeptide · Animal Model Evidence
Animal onlyEvidence level
SQ · Site unspecified · Frequency unknown
Vesugen
Bioregulatory Tripeptide · Vascular Endothelium
3 AATripeptide
Endothelin-1 ↓Atherosclerotic tissue
Ki-67 ↑Aged endothelium
SQ / IM · Protocol varies
01Mechanism of Action
Parameter
P21
Vesugen
Primary target
CNTF receptor alpha (CNTFRα) / LIF receptor (LIFR) / gp130 complex on neural stem cells
Vascular endothelial cell nucleus — MKI67 gene promoter
Pathway
CNTF mimetic → CNTFRα/LIFR/gp130 heterotrimer → JAK/STAT3 signaling → neurogenesis, stem cell proliferation, neuroprotection
KED → MKI67 promoter interaction (CATC binding motif -14 to +12 bp) → Ki-67 proliferation protein ↑
Downstream effect
Increased neural stem cell self-renewal, globose basal cell activation (Mash1+ cells), olfactory sensory neuron regeneration, hippocampal neurogenesis, neuroprotection in developmental disorders
Normalised endothelin-1 expression in atherosclerotic/restenotic endothelium, restored connexin expression for cell-cell communication, enhanced proliferative capacity in senescent endothelial culturesKozlov 2016Khavinson 2014
Feedback intact?
—
Not applicable — does not operate via hormone axis
Origin
Small-molecule peptide mimetic derived from full-length ciliary neurotrophic factor (CNTF), designed to retain receptor activation with improved pharmacokineticsMottolese 2024
Khavinson bioregulatory peptide school — designed as tissue-specific (vascular) cytomodulator
Antibody development
—
—
02Dosage Protocols
Parameter
P21
Vesugen
Human dosing
No established protocol
No clinical trial data available.
—
Animal models (mice)
Dose and route not specified in abstractsMottolese 2024Jia 2020
In vitro and in vivo studies demonstrate efficacy; precise dosing protocols not disclosed.
—
Evidence basis
Animal models only
CDKL5 KO mice, methimazole-induced olfactory injury, CNTF-/- knockout models.Mottolese 2024Cox 2026Jia 2020
Animal models (atherosclerosis, restenosis, aging) · Russian case series
Duration
Not specified
Case series report treatment courses in elderly arterial insufficiency
Route
Presumed subcutaneous or intraperitoneal (animal studies)
Subcutaneous or intramuscular
Standard dose (reported)
—
Not standardised — Russian clinical case series
Protocols vary; no FDA-approved regimen.
Frequency
—
Not specified in available literature
Half-life
—
Not reported
Tripeptides typically cleared rapidly.
04Side Effects & Safety
Parameter
P21
Vesugen
Human safety data
None available
No clinical trials in humans.
—
Animal tolerability
Well-tolerated in mouse models; no toxicity reported in available abstracts
—
Theoretical risks
Uncontrolled stem cell proliferation, immune response to peptide, unknown long-term CNS effects
—
Reported adverse events
—
None documented in available abstracts
Injection site
—
Assumed minimal — typical for small peptides
Long-term safety
—
Unknown — no long-term RCT data
Epigenetic mechanism risk
—
Theoretical concern: direct gene promoter interaction — proliferative effects in non-target tissues not characterised
Absolute Contraindications
P21
- ·Use in humans not validated
Vesugen
—Relative Contraindications
P21
- ·Active malignancy (theoretical — neurotrophic signaling may affect tumour growth)
- ·Pregnancy or lactation (no safety data)
Vesugen
- ·Active malignancy — proliferative mechanism (Ki-67 upregulation) untested in oncologic context
05Administration Protocol
Parameter
P21
Vesugen
1. Human protocol
Not established. No FDA approval, no clinical trial data.
Lyophilised powder reconstituted with sterile water or bacteriostatic water per supplier protocol. No standardised formulation.
2. Animal research context
In vivo studies used systemic administration (route not specified in abstracts) in mouse models of neurodegeneration, olfactory injury, and CDKL5 deficiency disorder. In vitro studies used primary cell cultures.
Subcutaneous (abdomen, thigh) or intramuscular. Rotate sites if multi-dose protocol.
3. Timing
—
No reported circadian or fasting requirement. Russian protocols typically integrated into geroprotective regimens.
4. Storage
—
Lyophilised: refrigerate 2–8 °C, light-protected. Reconstituted: use immediately or refrigerate per supplier guidance (typically <7 days).
06Stack Synergy
P21
— no documented stacks
Vesugen
+ Thymalin
Multi-pathwayBoth from Khavinson bioregulatory school. Thymalin targets thymic/immune axis, Vesugen targets vascular endothelium. Rationale: multi-system geroprotection in elderly — immune senescence + vascular aging. Documented in Khavinson-tradition protocols combining tissue-specific peptides for poly-organ rejuvenation. No direct synergy study; combinatorial logic based on distinct target tissues.
- Vesugen
- Per protocol (SQ/IM)
- Thymalin
- Per protocol (SQ/IM)
- Frequency
- Sequential or concurrent per geroprotective protocol
- Primary benefit
- Multi-system age-related decline mitigation (vascular + immune)